211 related articles for article (PubMed ID: 20591170)
1. The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells.
Mendoza-Villanueva D; Deng W; Lopez-Camacho C; Shore P
Mol Cancer; 2010 Jun; 9():171. PubMed ID: 20591170
[TBL] [Abstract][Full Text] [Related]
2. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.
Mendoza-Villanueva D; Zeef L; Shore P
Breast Cancer Res; 2011 Oct; 13(5):R106. PubMed ID: 22032690
[TBL] [Abstract][Full Text] [Related]
3. A role for CBFβ in maintaining the metastatic phenotype of breast cancer cells.
Ran R; Harrison H; Syamimi Ariffin N; Ayub R; Pegg HJ; Deng W; Mastro A; Ottewell PD; Mason SM; Blyth K; Holen I; Shore P
Oncogene; 2020 Mar; 39(12):2624-2637. PubMed ID: 32005976
[TBL] [Abstract][Full Text] [Related]
4. Core binding factor β of osteoblasts maintains cortical bone mass via stabilization of Runx2 in mice.
Lim KE; Park NR; Che X; Han MS; Jeong JH; Kim SY; Park CY; Akiyama H; Kim JE; Ryoo HM; Stein JL; Lian JB; Stein GS; Choi JY
J Bone Miner Res; 2015 Apr; 30(4):715-22. PubMed ID: 25358268
[TBL] [Abstract][Full Text] [Related]
5. The RUNX Transcriptional Coregulator, CBFβ, Suppresses Migration of ER
Pegg HJ; Harrison H; Rogerson C; Shore P
Mol Cancer Res; 2019 May; 17(5):1015-1023. PubMed ID: 30655324
[TBL] [Abstract][Full Text] [Related]
6. Association of core-binding factor β with the malignant phenotype of prostate and ovarian cancer cells.
Davis JN; Rogers D; Adams L; Yong T; Jung JS; Cheng B; Fennell K; Borazanci E; Moustafa YW; Sun A; Shi R; Glass J; Mathis JM; Williams BJ; Meyers S
J Cell Physiol; 2010 Nov; 225(3):875-87. PubMed ID: 20607802
[TBL] [Abstract][Full Text] [Related]
7. Cbfβ deletion in mice recapitulates cleidocranial dysplasia and reveals multiple functions of Cbfβ required for skeletal development.
Chen W; Ma J; Zhu G; Jules J; Wu M; McConnell M; Tian F; Paulson C; Zhou X; Wang L; Li YP
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8482-7. PubMed ID: 24850862
[TBL] [Abstract][Full Text] [Related]
8. Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers.
Illendula A; Gilmour J; Grembecka J; Tirumala VSS; Boulton A; Kuntimaddi A; Schmidt C; Wang L; Pulikkan JA; Zong H; Parlak M; Kuscu C; Pickin A; Zhou Y; Gao Y; Mishra L; Adli M; Castilla LH; Rajewski RA; Janes KA; Guzman ML; Bonifer C; Bushweller JH
EBioMedicine; 2016 Jun; 8():117-131. PubMed ID: 27428424
[TBL] [Abstract][Full Text] [Related]
9. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion.
Pratap J; Javed A; Languino LR; van Wijnen AJ; Stein JL; Stein GS; Lian JB
Mol Cell Biol; 2005 Oct; 25(19):8581-91. PubMed ID: 16166639
[TBL] [Abstract][Full Text] [Related]
10. The RUNX/CBFβ Complex in Breast Cancer: A Conundrum of Context.
Khan AS; Campbell KJ; Cameron ER; Blyth K
Cells; 2023 Feb; 12(4):. PubMed ID: 36831308
[TBL] [Abstract][Full Text] [Related]
11. Core binding factor β (CBFβ) is retained in the midbody during cytokinesis.
Lopez-Camacho C; van Wijnen AJ; Lian JB; Stein JL; Stein GS
J Cell Physiol; 2014 Oct; 229(10):1466-74. PubMed ID: 24648201
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells.
Pande S; Browne G; Padmanabhan S; Zaidi SK; Lian JB; van Wijnen AJ; Stein JL; Stein GS
J Cell Physiol; 2013 Aug; 228(8):1784-92. PubMed ID: 23389849
[TBL] [Abstract][Full Text] [Related]
13. Core-binding factor beta interacts with Runx2 and is required for skeletal development.
Yoshida CA; Furuichi T; Fujita T; Fukuyama R; Kanatani N; Kobayashi S; Satake M; Takada K; Komori T
Nat Genet; 2002 Dec; 32(4):633-8. PubMed ID: 12434152
[TBL] [Abstract][Full Text] [Related]
14. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo.
Javed A; Barnes GL; Pratap J; Antkowiak T; Gerstenfeld LC; van Wijnen AJ; Stein JL; Lian JB; Stein GS
Proc Natl Acad Sci U S A; 2005 Feb; 102(5):1454-9. PubMed ID: 15665096
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of core binding factorβ alters sphingolipid metabolism.
Greer AH; Yong T; Fennell K; Moustafa YW; Fowler M; Galiano F; Ng SW; Berkowitz RS; Cardelli J; Meyers S; Davis JN
J Cell Physiol; 2013 Dec; 228(12):2350-64. PubMed ID: 23813439
[TBL] [Abstract][Full Text] [Related]
16. Cbfbeta interacts with Runx2 and has a critical role in bone development.
Kundu M; Javed A; Jeon JP; Horner A; Shum L; Eckhaus M; Muenke M; Lian JB; Yang Y; Nuckolls GH; Stein GS; Liu PP
Nat Genet; 2002 Dec; 32(4):639-44. PubMed ID: 12434156
[TBL] [Abstract][Full Text] [Related]
17. CBFβ and the leukemogenic fusion protein CBFβ-SMMHC associate with mitotic chromosomes to epigenetically regulate ribosomal genes.
Lopez-Camacho C; van Wijnen AJ; Lian JB; Stein JL; Stein GS
J Cell Biochem; 2014 Dec; 115(12):2155-64. PubMed ID: 25079347
[TBL] [Abstract][Full Text] [Related]
18. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone.
Pratap J; Lian JB; Javed A; Barnes GL; van Wijnen AJ; Stein JL; Stein GS
Cancer Metastasis Rev; 2006 Dec; 25(4):589-600. PubMed ID: 17165130
[TBL] [Abstract][Full Text] [Related]
19. Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells.
San Martin IA; Varela N; Gaete M; Villegas K; Osorio M; Tapia JC; Antonelli M; Mancilla EE; Pereira BP; Nathan SS; Lian JB; Stein JL; Stein GS; van Wijnen AJ; Galindo M
J Cell Physiol; 2009 Dec; 221(3):560-71. PubMed ID: 19739101
[TBL] [Abstract][Full Text] [Related]
20. Runx2 in normal tissues and cancer cells: A developing story.
Blyth K; Vaillant F; Jenkins A; McDonald L; Pringle MA; Huser C; Stein T; Neil J; Cameron ER
Blood Cells Mol Dis; 2010 Aug; 45(2):117-23. PubMed ID: 20580290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
